Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.18 Million CAD | 364.23% |
| 2022 | 470.23 Thousand CAD | -44.72% |
| 2021 | 850.56 Thousand CAD | -31.51% |
| 2020 | 1.24 Million CAD | -19.81% |
| 2019 | 1.54 Million CAD | -38.3% |
| 2018 | 2.51 Million CAD | -6.61% |
| 2017 | 2.68 Million CAD | 177.47% |
| 2016 | 968.63 Thousand CAD | -30.67% |
| 2015 | 1.39 Million CAD | 107.43% |
| 2014 | 673.53 Thousand CAD | 30.66% |
| 2013 | 515.49 Thousand CAD | 453.97% |
| 2012 | 93.05 Thousand CAD | 0.56% |
| 2011 | 92.53 Thousand CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 3.31 Million CAD | 21.5% |
| 2024 Q1 | 2.34 Million CAD | 7.51% |
| 2024 Q2 | 2.73 Million CAD | 16.4% |
| 2023 Q1 | 411.95 Thousand CAD | -12.39% |
| 2023 Q3 | 1.65 Million CAD | 5.26% |
| 2023 Q2 | 1.57 Million CAD | 282.78% |
| 2023 Q4 | 2.18 Million CAD | 31.52% |
| 2023 FY | 2.18 Million CAD | 364.23% |
| 2022 Q4 | 470.23 Thousand CAD | -13.0% |
| 2022 Q3 | 540.51 Thousand CAD | -16.29% |
| 2022 Q1 | 770.47 Thousand CAD | -9.42% |
| 2022 Q2 | 645.72 Thousand CAD | -16.19% |
| 2022 FY | 470.23 Thousand CAD | -44.72% |
| 2021 Q4 | 850.56 Thousand CAD | -17.31% |
| 2021 FY | 850.56 Thousand CAD | -31.51% |
| 2021 Q2 | 1.03 Million CAD | -11.4% |
| 2021 Q1 | 1.17 Million CAD | -5.59% |
| 2021 Q3 | 1.02 Million CAD | -0.97% |
| 2020 Q1 | 1.23 Million CAD | -20.22% |
| 2020 FY | 1.24 Million CAD | -19.81% |
| 2020 Q3 | 1.32 Million CAD | 4.25% |
| 2020 Q2 | 1.27 Million CAD | 3.13% |
| 2020 Q4 | 1.24 Million CAD | -6.51% |
| 2019 FY | 1.54 Million CAD | -38.3% |
| 2019 Q4 | 1.54 Million CAD | -5.52% |
| 2019 Q2 | 1.94 Million CAD | -22.61% |
| 2019 Q1 | 2.5 Million CAD | -0.09% |
| 2019 Q3 | 1.63 Million CAD | -15.54% |
| 2018 Q4 | 2.51 Million CAD | -16.42% |
| 2018 FY | 2.51 Million CAD | -6.61% |
| 2018 Q3 | 3 Million CAD | 9.98% |
| 2018 Q2 | 2.73 Million CAD | 0.73% |
| 2018 Q1 | 2.71 Million CAD | 0.85% |
| 2017 Q2 | 1.67 Million CAD | 39.6% |
| 2017 Q1 | 1.19 Million CAD | 23.88% |
| 2017 Q3 | 2.21 Million CAD | 32.05% |
| 2017 FY | 2.68 Million CAD | 177.47% |
| 2017 Q4 | 2.68 Million CAD | 21.5% |
| 2016 FY | 968.63 Thousand CAD | -30.67% |
| 2016 Q2 | 723.54 Thousand CAD | -21.24% |
| 2016 Q3 | 983 Thousand CAD | 35.86% |
| 2016 Q1 | 918.65 Thousand CAD | -34.24% |
| 2016 Q4 | 968.63 Thousand CAD | -1.46% |
| 2015 Q4 | 1.39 Million CAD | 0.25% |
| 2015 FY | 1.39 Million CAD | 107.43% |
| 2015 Q3 | 1.39 Million CAD | 3.09% |
| 2015 Q2 | 1.35 Million CAD | -3.05% |
| 2015 Q1 | 1.39 Million CAD | 107.04% |
| 2014 Q3 | 567.47 Thousand CAD | 17.98% |
| 2014 Q2 | 480.99 Thousand CAD | -6.38% |
| 2014 Q4 | 673.53 Thousand CAD | 18.69% |
| 2014 FY | 673.53 Thousand CAD | 30.66% |
| 2014 Q1 | 513.75 Thousand CAD | -0.34% |
| 2013 Q4 | 515.49 Thousand CAD | 0.22% |
| 2013 Q3 | 514.35 Thousand CAD | -1.06% |
| 2013 Q2 | 519.85 Thousand CAD | 24.81% |
| 2013 Q1 | 416.5 Thousand CAD | 347.58% |
| 2013 FY | 515.49 Thousand CAD | 453.97% |
| 2012 Q2 | 55.18 Thousand CAD | -31.99% |
| 2012 Q4 | 93.05 Thousand CAD | 99.08% |
| 2012 Q3 | 46.74 Thousand CAD | -15.29% |
| 2012 Q1 | 81.13 Thousand CAD | -12.32% |
| 2012 FY | 93.05 Thousand CAD | 0.56% |
| 2011 FY | 92.53 Thousand CAD | 0.0% |
| 2011 Q4 | 92.53 Thousand CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2010 Q1 | 41 Thousand CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | -100.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 94.702% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 47.04% |
| SQZ Biotechnologies Company | 27.47 Million USD | 92.054% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 94.967% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 92.667% |
| Mesoblast Limited | 118.7 Million USD | 98.161% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -130.206% |
| Genus plc | 233.1 Million USD | 99.064% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 25.506% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -62.474% |
| Marizyme, Inc. | 18.71 Million USD | 88.337% |
| ContraFect Corporation | 2.88 Million USD | 24.229% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -191.063% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1511.205% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -50.933% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 6.147% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 61.42% |
| MultiCell Technologies, Inc. | 202.58 USD | -1077485.645% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 96.203% |
| EV Biologics, Inc. | 1.49 Million USD | -46.043% |
| Q BioMed Inc. | 4.1 Million USD | 46.886% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 93.405% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -246.461% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -77.714% |
| Biomind Labs Inc. | 735.54 Thousand USD | -196.784% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.727% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 83.204% |
| Skye Bioscience, Inc. | 4.61 Million USD | 52.701% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -145.813% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1442.541% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 62.818% |
| IMV Inc. | 28.88 Million USD | 92.442% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -8387.783% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 3.339% |
| GB Sciences, Inc. | 1.75 Million USD | -24.081% |
| Alpha Cognition Inc. | 1.22 Million USD | -78.878% |
| HST Global, Inc. | 98.31 Thousand USD | -2120.296% |
| CSL Limited | 12.18 Billion USD | 99.982% |
| Halberd Corporation | 150 Thousand USD | -1355.315% |
| Enzolytics Inc. | 996.33 Thousand USD | -119.1% |
| Resverlogix Corp. | 6.49 Million USD | 66.369% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -357.167% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -754.085% |
| argenx SE | 20 Million USD | 89.085% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 95.209% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 19.409% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -21249.369% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.477% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -988.135% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 8.956% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -852.054% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 96.773% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 27.864% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -506.87% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 89.261% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1368.493% |
| BioStem Technologies, Inc. | 4.71 Million USD | 53.666% |
| ONE Bio Corp. | 19.71 Million USD | 88.927% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -772.554% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -777.683% |
| Agentix Corp. | 50 Thousand USD | -4265.946% |
| LadRx Corporation | 33.6 Thousand USD | -6395.783% |
| Cell Source, Inc. | 9.25 Million USD | 76.411% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -188.675% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -188.675% |
| NovAccess Global Inc. | 2.19 Million USD | 0.769% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 69.136% |
| Itoco Inc. | 228.37 Thousand USD | -855.864% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -934.707% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 56.192% |
| Kadimastem Ltd | 891.22 Thousand USD | -144.94% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -443.232% |
| CytoDyn Inc. | 30.07 Million USD | 92.742% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -350.763% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -520.432% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 72.085% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1682.019% |
| Rebus Holdings, Inc. | 310 Thousand USD | -604.185% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 53.9% |
| International Stem Cell Corporation | 4.17 Million USD | 47.751% |
| Bioxytran, Inc. | 1.92 Million USD | -13.401% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3397.625% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -0.095% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 73.75% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 74.572% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -40.341% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -714.542% |
| Neutra Corp. | 54.15 Thousand USD | -3930.898% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -19.288% |
| PureTech Health plc | 25.51 Million USD | 91.443% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -78.315% |
| IXICO plc | 472.02 Thousand USD | -362.472% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 85.917% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 96.494% |
| CSL Limited | 12.18 Billion USD | 99.982% |
| Cellectis S.A. | 92.77 Million USD | 97.647% |